Peripheral blood mononuclear cells (PBMC) derived from healthy individuals were stimulated with u.v.-inactivated Newcastle disease virus and the cell supernatants were assayed for both antiviral activity and alpha interferon (IFN-~) immunoreactivity. IFN-ct concentrations determined by two immunoradiometric assays (IRMAs) based on monoclonal antibodies that recognize different IFN-u subtypes correlated well together (r = 0.96) and with interferon concentrations determined by the two bioassays (r = 0-82 to 0.89), but the agreement between the results of the two bioassays was not as close (r = 0.79). As judged by the agreement between determinations on duplicate inductions of the same PBMC, the IRMAs were considerably more precise than the bioassays. Despite the use of a common IFN standard there were marked differences in the absolute titres of IFN determined by the IRMAs and bioassays, highlighting the difficulties in standardizing assays for IFN-u. The IRMA results suggest that there are no major differences in the spectrum of IFN-~ subtypes produced by healthy individuals under conditions of viral stimulation.
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In man, it is suggested that virus-induced interferon alpha (IFN-~) production is part of the innate immune response to natural virus infections. A multiplicity of genes code for different human leukocyte-derived IFN-u subtypes (Goeddel et al., 1981) . A suspension of Namalwa lymphoblasts makes at least eight IFN-c( subtypes when stimulated with Sendai virus (Allen & Fantes, 1980) and it is likely that IFN-u derived from pooled buffy coat leukocytes consists of a similarly heterogeneous mixture. However, it is not clear whether an individual has the capacity to produce all IFN-~ subtypes and actually does so during a viral infection. The observation that some patients raise neutralizing antibodies to exogenous IFNs given for therapeutic purposes (Vallbracht et al., 1981 ; Mogensen et al., 1981 , Trown et al., 1983 could be explained by the recognition of these exogenous IFN subtypes as 'foreign' proteins.
In the present study, we set out to determine whether peripheral blood mononuclear cells (PBMC) from a number of healthy individuals produced different profiles of IFN-ct subtypes when stimulated by virus. In order to investigate this possibility, results obtained for each sample with two biological assays using two cell lines, and with two immunoradiometric assays (IRMAs) based on different monoclonal antibodies, were compared.
Heparinized venous blood samples were obtained from healthy laboratory and hospital staff on one morning and were treated under identical conditions. Twenty-four individuals were tested on the first study day (sample 1). Four months later 16 of these individuals were available to give blood on the second study day (sample 2). PBMC were separated on Ficoll-Paque (Pharmacia) and washed three times with medium RPMI 1640. Cells were resuspended at 106 cells/ml and 1 ml volumes were incubated in duplicate for 24 h at 37°C with 80 haemagglutinating units of u.v.-inactivated Newcastle disease virus in RPMI 1640 medium with 2~o foetal calf serum. Samples were agitated gently on three occasions during the incubatiOn. After centrifugation at 5000 r.p.m, for 10 min, cell supernatants were harvested and frozen in aliquots at -70 °C for later assays.
IFN antiviral activity was measured by observing the dilution that causd 50 % reduction of the cytopathic effect (c.p.e.) of Semliki Forest virus (50 TCIDso) in confluent monolayers of continuous human epithelial carcinoma cells (HEp-2, Flow Laboratories) or embryonic bovine tracheal cells (EBTr, Flow Laboratories). Assays were performed in duplicate in microtitre plates, with threefold dilution steps. The same dilutions were used for the assays in both cell lines and run in parallel. C.p.e. was judged microscopically and after staining with crystal violet. Titres were standardized against leukocyte interferon MRC 69/19B (National Institute for Biological Standards & Control, London, U.K.). IFN immunoreactivity was measured by an IRMA technique (SUCROSEP Serum IFN<t IRMA; Boots-Celltech Diagnostics Ltd.). Samples were incubated with 125I-labelled monoclonal antibody INK2 (Secher & Burke, 1980) or YOK 5/19] for 2 h at room temperature (20 °C). Excess solid-phase sheep anti-IFN<t immunoglobulin was then added to the reaction mixture and incubated for a further 2 h at room temperature with continuous agitation. Labelled monoclonal antibody associated with IFN and solid phase was separated and washed by the Sucrosep non-centrifugation separation system of Wright & Hunter (1983) and counted for radioactivity. Assays were performed in duplicate and IFN-~ concentrations for unknown samples interpolated from a standard curve of a leukocyte IFN-ct preparation previously standardized against MRC 69/19B in the same assay.
The IFN-ct subtype recognition properties of the two monoclonal antibodies are shown in Fig.  1 . Although two pooled buffy coat leukocyte interferon preparations gave similar dose-response curves in each IRMA, recombinant DNA-derived IFN-cq was not recognized by NK2 while IFN-ct: was bound by YOK 5/19 only when present at high concentration. Thus, the IRMAs display some IFN-ct subtype specificity depending upon the labelled monoclonal antibody selected for use. Comparisons between IFN titres obtained from every sample (duplicate inductions included) from 16 individuals are shown for IRMAs (Fig. 2 ) and for bioassays (Fig. 3) . IFN-c¢ concentrations estimated by IRMAs using the two monoclonal antibodies with different IFN-cx subtype specificities were in good agreement. By comparison, for many samples, there was poorer correspondence between the results for the bioassays on the two cell lines, despite the standardization on each plate with the same leukocyte IFN standard. The geometric mean titres of IFN by each assay for all the samples are given in Table 1 . These results indicate that while there was acceptable agreement between the titres of IFN in the parallel duplicate inductions of each PBMC sample by each assay, this agreement was worse between bioassays than between IRMAs. This reduced assay precision is probably due to innate biological variation in the bioassay method and contributes to the poorer correlation observed between bioassays than between IRMA ( Fig. 1 and 2) .
Our results indicate that even though the two monoclonal antibody-based IRMAs show considerable IFN<z specificity when tested with pure, recombinant DNA-derived subtype preparations, they recognize approximately equivalent amounts of immunoreactive IFN in PBMC supernatants. By contrast, poor correspondence was seen between the antiviral titres of these supernatants using two different cell lines. The higher antiviral activity of human leukocyte IFN in bovine cells first noted by Gresser et al. (1974) is probably primarily due to IFN-% which gives 10-to 20-fold higher titres than IFN-c~ 2 in bovine cells, compared with approximately sixfold lower titres on human amnion (WISH) cells (Weck et al., 1981) . Despite this difference, after correction with a leukocyte IFN standard, geometric mean titres between the bioassays were not statistically different.
Titres of IFN achieved by measuring antiviral activity were consistently higher than those determined by IRMA despite the use of a common standard (Table 2) . This may reflect an underlying difference in standardization between the IRMA and the c.p.e.-inhibition assays (which are less amenable to numerical treatment).
There is, of course, a fundamental difference in the way biological and immunoreactive titres are devised. Biological titres are diluted until a biological endpoint (50% virus inhibition) is obtained and such a titre is thus an approximation, the accuracy of which depends upon the dilution steps selected. Furthermore, two such approximations must be made when the unknown is compared with the standard. Immunoreactive titres are based on an immunological endpoint and are interpolated from a continuous standard curve constructed from dilutions of an IFN preparation previously calibrated for 'antiviral' behaviour. A likely explanation for the observed difference is thus that the potency of the assay standard is critically dependent on its IFN subtype composition. For example, consider a 100 U/ml preparation containing an IFN-~1 :IFN-a2 ratio of 1:4. This will give a potency of 100 U/ml in a bioassay (by definition). A similar working standard containing the reverse subtype ratio (4 : 1) will also give a potency of 100 U/ml in a bioassay. However, the original standard (1:4) might give titres of say about 80 U/ml in the YOK 5/19 IRMA (which barely recognizes IFN-~2) but only 20 U/ml in the NK2 IRMA (which does not recognize IFN-a0. The observation that samples from all individuals gave higher titres of IFN on the second occasion compared to the first (Table 2) probably represents some uncontrolled variation in induction conditions between the two occasions although others have noted a seasonal variation in IFN production (Georgiades et al., 1983) . Although some differences were observed between IFN titres on different bioassays, the excellent correlation between IFN titres with the two monoclonai antibody-based IRMAs suggests that this variation is not due to major differences in the proportions of IFN-a subtypes produced by PBMC from healthy volunteers on viral stimulation. It may rather reflect relative imprecision in the performance of the bioassays.
This study further highlights problems in the definition, standardization and comparison of mixed IFN preparations, but suggests that the availability of specific, monoclonal antibodybased IRMAs which display high analytical precision may allow the complexity of the human IFN system to be partially dissected.
